Literature DB >> 23142225

Elevated chemokine CC-motif receptor-like 2 (CCRL2) promotes cell migration and invasion in glioblastoma.

Fengqiong Yin1, Zhenhua Xu, Zifeng Wang, Hong Yao, Zan Shen, Fang Yu, Yiping Tang, Dengli Fu, Sheng Lin, Gang Lu, Hsiang-Fu Kung, Wai Sang Poon, Yunchao Huang, Marie Chia-Mi Lin.   

Abstract

Chemokine CC-motif receptor-like 2 (CCRL2) is a 7-transmembrane G protein-coupled receptor which plays a key role in lung dendritic cell trafficking to peripheral lymph nodes. The function and expression of CCRL2 in cancer is not understood at present. Here we report that CCRL2 expression level is elevated in human glioma patient samples and cell lines. The magnitude of increase is positively associated with increasing tumor grade, with the highest level observed in grade IV glioblastoma. By gain-of-function and loss-of-function studies, we further showed that CCRL2 did not regulate the growth of human glioblatoma U87 and U373 cells. Importantly, we demonstrated that over-expression of CCRL2 significantly enhanced the migration rate and invasiveness of the glioblastoma cells. Taken together, these results suggest for the first time that elevated CCRL2 in glioma promotes cell migration and invasion. The potential roles of CCRL2 as a novel therapeutic target and biomarker warrant further investigations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142225     DOI: 10.1016/j.bbrc.2012.10.120

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells.

Authors:  Lei-Ping Wang; Jun Cao; Jian Zhang; Bi-Yun Wang; Xi-Chun Hu; Zhi-Min Shao; Zhong-Hua Wang; Zhou-Luo Ou
Journal:  Med Oncol       Date:  2015-10-20       Impact factor: 3.064

2.  The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.

Authors:  Annalisa Del Prete; Francesca Sozio; Tiziana Schioppa; Andrea Ponzetta; William Vermi; Stefano Calza; Mattia Bugatti; Valentina Salvi; Giovanni Bernardini; Federica Benvenuti; Annunciata Vecchi; Barbara Bottazzi; Alberto Mantovani; Silvano Sozzani
Journal:  Cancer Immunol Res       Date:  2019-09-04       Impact factor: 11.151

3.  High expression of CRAM correlates with poor prognosis in patients with cervical carcinoma.

Authors:  Teng Hou; Dongxia Liang; Dong Yang; Jiehua He; Yongwen Huang; Yanna Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

4.  Residual Ammonium Persulfate in Nanoparticles Has Cytotoxic Effects on Cells through Epithelial-Mesenchymal Transition.

Authors:  Chen Song; Leyu Wang; Genlan Ye; Xiaoping Song; Yutong He; Xiaozhong Qiu
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

5.  Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration.

Authors:  Vida Farsam; Abhijit Basu; Martina Gatzka; Nicolai Treiber; Lars A Schneider; Medhanie A Mulaw; Tanja Lucas; Stefan Kochanek; Reinhard Dummer; Mitchell P Levesque; Meinhard Wlaschek; Karin Scharffetter-Kochanek
Journal:  Oncotarget       Date:  2016-12-13

Review 6.  The Role of Selected Chemokines and Their Receptors in the Development of Gliomas.

Authors:  Magdalena Groblewska; Ala Litman-Zawadzka; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

7.  Atypical chemokine receptor CCRL2 is overexpressed in prostate cancer cells.

Authors:  Niradiz Reyes; Ines Benedetti; Juan Rebollo; Jan Geliebter
Journal:  J Biomed Res       Date:  2017-11-01

Review 8.  CXC and CC chemokines as angiogenic modulators in nonhaematological tumors.

Authors:  Matteo Santoni; Sergio Bracarda; Massimo Nabissi; Francesco Massari; Alessandro Conti; Emilio Bria; Giampaolo Tortora; Giorgio Santoni; Stefano Cascinu
Journal:  Biomed Res Int       Date:  2014-05-29       Impact factor: 3.411

9.  Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways.

Authors:  Qian Rong Liu; Ju Mei Liu; Yong Chen; Xiao Qiang Xie; Xin Xin Xiong; Xin Yao Qiu; Feng Pan; Di Liu; Shang Bin Yu; Xiao Qian Chen
Journal:  Oxid Med Cell Longev       Date:  2014-05-22       Impact factor: 6.543

10.  Reduced expression of chemerin is associated with poor clinical outcome in acute myeloid leukemia.

Authors:  Jing Zhang; Jiao Zhou; Xi Tang; Ling-Yu Zhou; Ling-Ling Zhai; Minse Evola-Deniz Vanessa; Jing Yi; Yun-Yun Yi; Jiang Lin; Jun Qian; Zhao-Qun Deng
Journal:  Oncotarget       Date:  2017-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.